Feasibility of erlotinib after gefitinib failure in patients with advanced pulmonary adenocarcinoma previously responding to gefitinib.
- Author:
Zi-jin ZHANG
1
;
Ping ZHANG
;
Xiao-nan WU
;
Lin LI
;
Gang CHENG
Author Information
- Publication Type:Journal Article
- MeSH: Adenocarcinoma; drug therapy; Aged; Aged, 80 and over; Antineoplastic Agents; therapeutic use; Drug Tolerance; Erlotinib Hydrochloride; Feasibility Studies; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; drug therapy; Male; Middle Aged; Quinazolines; therapeutic use; Retrospective Studies; Treatment Outcome
- From: Acta Academiae Medicinae Sinicae 2010;32(4):371-374
- CountryChina
- Language:English
-
Abstract:
OBJECTIVETo evaluate the efficacy and progression-free survival of erlotinib after progression of disease to gefitinib in patients with advanced pulmonary adenocarcinoma who previously obtained a disease control with gefitinib.
METHODIn this retrospective study, 12 patients with advanced or metastatic pulmonary adenocarcinoma,who were previously obtained a partial response or a stable disease with gefitinib,were treated with erlotinib after gefitinib failure. Erlotinib efficiency, progression-free survival and overall survival were analyzed.
RESULTSNice (75%)achieved stable disease and three (25%) achieved progression disease with erlotinib treatment after gefitinib failure. No complete response or partial response was observed. The disease control rate was 75%. The median progression-free survival and overall survival of erlotinib were 180 days and 831 days.
CONCLUSIONErlotinib seems to be an optional treatment after gefitinib failure for advanced pulmonary adenocarcinoma patients,who previously responded to gefitinib.
